LEP and metabolic dysfunction-associated steatohepatitis: Recombinant leptin has been successfully used in the treatment of insulin resistance and hepatic steatosis in patients with lipodystrophy and NASH (Oral et al., 2002; Petersen et al., 2002; Javor et al., 2005).